Immune cell-redirecting, CD3-targeted/TAA-targeted BsAbs have used TAAs such as EGFR, HER2, and c-Met, whereas TSAs like EGFRvIII (254), p95HER2 (255), and RAS G12V are more desirable targets to prevent on-target, off-tumor impacts caused by target expression on healthy cells. Here, ERBB2 is linked to neoplasm.